NM_058216.3:c.493A>G (p.Met165Val) in RAD51C is a missense variant in exon 3. The ClinGen Hereditary Breast, Ovarian and Pancreatic Cancer Expert Panel specification for RAD51C (version 1.0.0) does not provide criterion-level rules; assessment follows generic ACMG/AMP 2015 guidelines.¹ This variant is absent from gnomAD v2.1 and gnomAD-Canada and is extremely rare in gnomAD v4.1 (overall allele frequency 0.00012%, 2/1,614,182 alleles), meeting PM2 at supporting strength.² Multiple in silico tools predict a benign effect: REVEL score 0.046, BayesDel score -0.475, and SpliceAI max delta 0.00, meeting BP4 at supporting strength.³ ClinVar reports this variant as uncertain significance (3 clinical laboratories) and benign (1 clinical laboratory). No expert panel classification is available. No publication identified mentions this specific variant.⁴ No functional studies, segregation data, case-control analyses, or de novo observations were identified for this variant. The variant has not been characterized experimentally. With PM2 (supporting) and BP4 (supporting) as the only applicable criteria, the evidence is balanced but insufficient for a definitive classification; the variant remains a variant of uncertain significance.